Century Reports Flat Loss in Fiscal Q2

Century Therapeutics (NASDAQ:IPSC), an early-stage biotechnology company pioneering cell therapies using induced pluripotent stem cell (iPSC) technology, reported its second quarter 2025 financial results on August 14, 2025, for the period ending June 30. The most notable announcement was that results were exactly in line with analyst expectations, with a net loss per share of $0.3761 (GAAP) and no reported revenue, as anticipated for a pre-commercial, development-focused biotech at this stage. Overall, Century demonstrated cost discipline by slightly reducing both research and administrative expenses compared to the prior year, though its net loss (GAAP) widened marginally. Progress was reported on the company’s lead pipeline assets, particularly the ongoing clinical trials for CNTY-101, but commercial traction and meaningful revenue remain distant, as GAAP revenue was $0. The company’s cash position remains solid, supported by recent operational changes that extend its cash runway into the fourth quarter of 2027. Slow enrollment and limited early data indicate continued execution risks. Source: Analyst estimates for the quarter provided by FactSet. Century is developing next-generation cell therapies for cancer and autoimmune diseases using its proprietary iPSC platform. The company’s core technology platform enables it to precisely engineer immune cells to evade immune rejection, potentially allowing repeated dosing and expanded patient access. Its leading product candidates target unmet needs in B-cell-mediated autoimmune diseases and select malignancies.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool